Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first-line therapy for triple-negative, metastatic, or locally advanced breast cancer: Results from the GINECO A-TaXel phase 2 study-Reference-Cited by-同舟云学术

Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first-line therapy for triple-negative, metastatic, or locally advanced breast cancer: Results from the GINECO A-TaXel phase 2 study

Published:2016-07-14 Issue:20 Volume:122 Page:3119-3126
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Ferrero Jean-Marc¹,Hardy-Bessard Anne-Claire²,Capitain Olivier³,Lortholary Alain⁴,Salles Bruno⁵,Follana Philippe¹,Herve Robert⁶,Deblock Mathilde⁷,Dauba Jérôme⁸,Atlassi Mustapha⁹,Largillier Rémy¹⁰

Affiliation:

1. Department of Medical Oncology, Antoine-Lacassagne Centre; Nice France

2. Armorican Radiology Clinic; Saint-Brieuc France

3. Department of Medical Oncology, Paul Papin Western Oncology Institute; Angers France

4. Catherine of Sienne Centre; Nantes France

5. Department of Medical Oncology, William Morey Hospital; Chalon-sur-Saone France

6. Clairval Private Hospital; Marseille France

7. Department of Medical Oncology, Lorraine Cancer Institute; Vandoeuvre-les-Nancy France

8. Department of Medical Oncology, Mont de Marsan Hospital; Mont de Marsan France

9. Department of Medical Oncology, Le Mans Hospital; Le Mans France

10. Azure Cancer Centre; Mougins France

Funder

Roche France

Ligue Nationale contre le Cancer

ARCAGY-GINECO (Association de Recherche sur les CAncers dont GYnecologiques/Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens et du sein)

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference28 articles.

1. A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer;Jerusalem;Cancer Treat Rev.,2015

2. Palbociclib in hormone-receptor-positive advanced breast cancer;Turner;N Engl J Med.,2015

3. HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development;Singh;Br J Cancer.,2014

4. Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition;Audeh;Pharmgenomics Pers Med.,2014

5. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2);Cardoso;Ann Oncol.,2014

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancing targeted combination chemotherapy in triple negative breast cancer: nucleolin aptamer-mediated controlled drug release;Journal of Translational Medicine;2024-07-01

2. Advancing Targeted Combination Chemotherapy in Triple Negative Breast Cancer: Nucleolin Aptamer-Mediated Controlled Drug Release;2024-03-27

3. Apatinib plus etoposide in pretreated patients with advanced triple-negative breast cancer: a phase II trial;BMC Cancer;2023-05-19

4. Discovery of a first-in-class ANXA3 degrader for the treatment of triple-negative breast cancer;Acta Pharmaceutica Sinica B;2023-04

5. The prognosis and risk factors for capecitabine maintenance treatment in metastatic breast cancer: a retrospective comparative cohort study;Annals of Translational Medicine;2022-09